Search results
13 kwi 2021 · Among patients with BM from lung cancer, RT was also associated with a survival difference after 1 year (57.3% vs. 32.8%, P < 0.001) and a median survival increase of 3.7 months. The 1-year...
- Full Size Table
Chętnie wyświetlilibyśmy opis, ale witryna, którą oglądasz,...
- Full Size Table
Among patients with BM from lung cancer, RT was also associated with a survival difference after 1 year (57.3% vs. 32.8%, P < 0.001) and a median survival increase of 3.7 months. The 1-year overall survival rate was significantly better for SRS than for WBRT (46.4% vs. 38.8%, P < 0.001).
15 wrz 2020 · Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3-17 months, and 4-35 months, respectively.
4 cze 2023 · Up to a third of cancer patients go onto developing brain metastasis, with lung and breast cancer accounting for most cases. The average survival from the time of diagnosis ranges from 2 to 7 months.
specific survival rate were lower at 33.3%; however, the difference observed was not significant (overall survival rate, p ¼ 0.472; disease-specific survival rate, p ¼ 0.397).
19 paź 2023 · We performed a systematic review and meta-analysis to assess overall survival of patients with ten or more brain metastases treated with stereotactic radiosurgery as primary therapy. The search strings were applied to MEDLINE, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL).
Among patients with BM from lung cancer, RT was also associated with a survival diference after 1 year (57.3% vs. 32.8%, P < 0.001) and a median survival increase of 3.7 months. The 1‐year...
